Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
09/15/20173:46AMDJNIndivior Files New Lawsuits for Alleged Patent Infringement
By Adria Calatayud Indivior PLC (INDV.LN) said Friday that its U.S. subsidiary, Indivior Inc., has filed lawsuits against six competitors for alleged patent infringement after having recently lost another U.S. patent litigation for the same product. The U.K.-based pharmaceutical company said the lawsuits were filed against... More...>>
09/14/201712:03PMPRNUSMylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets
Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Sept. 14, 2017 HERTFORDSHIRE, England and PITTSBURGH, Sept. 14, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Norethindrone Acetate and... More...>>
09/13/20178:00AMPRNUSMylan Names Dennis Zeleny as Chief Human Relations Officer
Mylan Names Dennis Zeleny as Chief Human Relations Officer PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Sept. 13, 2017 HERTFORDSHIRE, England and PITTSBURGH, Sept. 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Dennis Zeleny as chief human relations officer. Zeleny joins... More...>>
09/09/20173:02AMDJNPatents Take Refuge With Indian Tribe -- WSJ
By Jonathan D. Rockoff This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (September 9, 2017). Allergan PLC has taken a novel step to protect top-selling drug Restasis from generic competition: The company has sold... More...>>
09/08/20174:59PMDJNAllergan Partners With Indian Tribe to Protect Drug Patents -- 3rd Update
By Jonathan D. Rockoff Allergan PLC has taken a novel step to protect top-selling drug Restasis from generic competition: the company has sold the drug's patents to an Indian tribe in upstate New York to block rivals from challenging the patents at the U.S. Patent and Trademark Office. The St. Regis Mohawk Tribe... More...>>
09/07/20177:45PMDJNFDA Warns Pfizer's Meridian Unit on EpiPen Oversight, Quality Issues
By Thomas M. Burton The Food and Drug Administration issued a scathing warning letter to a Pfizer Inc. unit that manufactures the emergency auto-injector EpiPen, saying the company "failed to thoroughly investigate" product failures even in cases of patients' deaths. The EpiPen, sold by Mylan NV, is manufactured... More...>>
08/24/20173:00AMPRNUSOtsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba™) for Multidrug-Resistant Tuberculosis (MDR...
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba™) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries PR Newswire TOKYO, HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2017 TOKYO, HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2017 /PRNewswire/ -- Otsuka Pharmaceutical... More...>>
08/17/201710:43AMPRNUSMylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen® Auto-Injector
Mylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen® Auto-Injector PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 17, 2017 HERTFORDSHIRE, England and PITTSBURGH, Aug. 17, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its subsidiaries, Mylan Inc. and Mylan... More...>>
08/11/20176:27PMDJNEngland's NHS Turns to Clinical Trial to Make Cheaper HIV Drug Available -- 2nd Update
By Donato Paolo Mancini A branded HIV drug that has been shown to reduce the risk of infection with the virus by 86% is proving too expensive for some at-risk European patients. England's National Health Service thinks it has a solution. By rolling out the treatment under the banner of a clinical trial, the NHS can... More...>>
08/11/20171:18PMDJNEngland's NHS Turns to Clinical Trial to Make Cheaper HIV Drug Available -- Update
By Donato Paolo Mancini A branded HIV drug that's been shown to reduce the risk of infection with the virus by 86% is proving too expensive for some at-risk European patients. England's National Health Service thinks it has a solution. By rolling out the treatment under the banner of a clinical trial, the NHS... More...>>
08/11/20175:15AMDJNEngland's NHS Turns to Clinical Trial to Make Cheaper HIV Drug Available
By Donato Paolo Mancini LONDON--A branded HIV drug that is been shown to reduce the risk of infection with the virus by 86% is proving too expensive for some at-risk European patients. England's National Health Service thinks it has a solution. The high price of Gilead Sciences Inc.'s HIV drug Truvada has deterred... More...>>
08/10/20178:00AMPRNCAMylan élargit l'accès aux traitements contre le VIH en lançant trois antirétroviraux génériques sur le marché canadien
Mylan élargit l'accès aux traitements contre le VIH en lançant trois antirétroviraux génériques sur le marché canadien Canada NewsWire HERTFORDSHIRE, Angleterre, PITTSBURGH et TORONTO, le 10 août 2017 Mylan offre maintenant des options génériques comme solution de rechange... More...>>
08/10/20178:00AMPRNCAMylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada Canada NewsWire HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1 HERTFORDSHIRE, England and... More...>>
08/10/20178:00AMPRNUSMylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada PR Newswire HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1 HERTFORDSHIRE, England and PITTSBURGH... More...>>
08/10/20173:02AMDJNMylan Cuts View On Drug Delays -- WSJ
By Imani Moise and Cara Lombardo This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (August 10, 2017). Mylan NV cut its earnings forecast for the next year and a half as the company faces increased competition from... More...>>
08/09/20176:17PMDJNMylan Defers Product Launches -- 3rd Update
By Imani Moise and Cara Lombardo Mylan NV cut its earnings forecast for the next year and a half as the company faces increased competition from generic drugs and delays in the launch of key drugs amid regulatory questions. The company said it couldn't count on launching this year the planned generic versions of Teva... More...>>
08/09/20172:00PMDJNMylan Defers Product Launches -- Update
By Imani Moise and Cara Lombardo Mylan NV cut its earnings forecast for the next year and a half as the company faces increased competition from generic drugs and delays in the launch of key drugs amid regulatory questions. The company said it couldn't count on launching this year planned generic versions of Teva... More...>>
08/09/20171:33PMDJNCorrection to article on Mylan earnings
The Food and Drug Administration earlier this year asked for more information on Mylan drugs in development. "Mylan Defers Product Launches," at 9:42 ET, incorrectly gave the name of the agency as the Federal Drug Administration in the fourth paragraph. (Aug. 9) (END) Dow Jones Newswires August 09, 2017 13:18... More...>>
08/09/20178:00AMPRNUSMylan Reports Second Quarter 2017 Results and Updates 2017 Guidance
Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 9, 2017 HERTFORDSHIRE, England and PITTSBURGH, Aug. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and six months ended June 30, 2017... More...>>
08/08/20171:30AMPRNUSMylan Launches Avonza™ in India
Mylan Launches Avonza™ in India Mylan is first to offer innovative, reduced-dose HIV treatment in India WHO recommended antiretroviral is helping to expand access to patients in India at a lower cost PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 8, 2017 HERTFORDSHIRE, England and PITTSBURGH, Aug. 8, 2017 /PRNewswire/... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20170926 02:06:32